Semaglutide, a glucagon like peptide-1 (GLP-1) receptor agonist, is available as monotherapy in both equally subcutaneous as well as oral dosage form (first authorised oral GLP-1 receptor agonist). It's been authorised like a next line treatment option for better glycaemic control in style 2 diabetic issues and at present below https://hilaired307uus8.corpfinwiki.com/user